Acidity changes immunology: a new VISTA pathway
January 21, 2020
- Using the LRC-TriCEPS platform PSGL-1 was identified as the interaction partner of the co-inhibitor Vista on activated primary T-cells as at acidic pH mimicking the acidic tumour environment
- Now, Vista tumour immunotherapy can rationally move forward
- The results also suggest to use also acidity as therapeutic target for tumour therapy
- Now also other interactions at acidic pH for drug candidates or co-inhibitor interactions should be tested on primary T-cells. It could explain why some drug candidates are not successful in later development.
Kathleen M. Mahoney and Gordon J. Freeman